Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study

A Braat; RCG Bruijnen; R Rooij; M Braat; FJ Wessels; RS Van Leeuwaarde; MJC Treijen; W.W. de Herder; Hans Hofland; MET Tesselaar; H Jong; M Lam

doi:10.1016/s1470-2045(20)30027-9

Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study

A Braat
, RCG Bruijnen
, R Rooij
, M Braat
, FJ Wessels
, RS Van Leeuwaarde
, MJC Treijen
, W.W. de Herder
, Hans Hofland
, MET Tesselaar
, H Jong
, M Lam

Internal Medicine

Research output: Contribution to journal › Article › Academic › peer-review

64 Citations (Scopus)

Original language	English
Pages (from-to)	561-570
Number of pages	10
Journal	Lancet Oncology
Volume	21
Issue number	4
DOIs	https://doi.org/10.1016/s1470-2045(20)30027-9
Publication status	Published - 2020

Research programs

EMC OR-01

Access to Document

10.1016/s1470-2045(20)30027-9

http://hdl.handle.net/1765/128383

Cite this

Braat, A., Bruijnen, RCG., Rooij, R., Braat, M., Wessels, FJ., Van Leeuwaarde, RS., Treijen, MJC., de Herder, W. W., Hofland, H., Tesselaar, MET., Jong, H., & Lam, M. (2020). Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncology, 21(4), 561-570. https://doi.org/10.1016/s1470-2045(20)30027-9

@article{86fb41020b604c34bbcfd29e4ae401f9,

title = "Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study",

author = "A Braat and RCG Bruijnen and R Rooij and M Braat and FJ Wessels and \{Van Leeuwaarde\}, RS and MJC Treijen and \{de Herder\}, W.W. and Hans Hofland and MET Tesselaar and H Jong and M Lam",

year = "2020",

doi = "10.1016/s1470-2045(20)30027-9",

language = "English",

volume = "21",

pages = "561--570",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "4",

}

Braat, A, Bruijnen, RCG, Rooij, R, Braat, M, Wessels, FJ, Van Leeuwaarde, RS, Treijen, MJC, de Herder, WW , Hofland, H, Tesselaar, MET, Jong, H & Lam, M 2020, 'Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study', Lancet Oncology, vol. 21, no. 4, pp. 561-570. https://doi.org/10.1016/s1470-2045(20)30027-9

Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. / Braat, A; Bruijnen, RCG; Rooij, R et al.
In: Lancet Oncology, Vol. 21, No. 4, 2020, p. 561-570.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study

AU - Braat, A

AU - Bruijnen, RCG

AU - Rooij, R

AU - Braat, M

AU - Wessels, FJ

AU - Van Leeuwaarde, RS

AU - Treijen, MJC

AU - de Herder, W.W.

AU - Hofland, Hans

AU - Tesselaar, MET

AU - Jong, H

AU - Lam, M

PY - 2020

Y1 - 2020

U2 - 10.1016/s1470-2045(20)30027-9

DO - 10.1016/s1470-2045(20)30027-9

M3 - Article

SN - 1470-2045

VL - 21

SP - 561

EP - 570

JO - Lancet Oncology

JF - Lancet Oncology

IS - 4

ER -